News

Incyte price target raised to $87 from $86 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm ...
Bank of America Securities Sticks to Its Buy Rating for Incyte (INCY)
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...
Incyte Corp. stock underperforms Wednesday when compared to competitors
Shares of Incyte Corp. INCY slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...
Barchart on MSN4d
Incyte Earnings Preview: What to Expect
Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...
Buy or sell: Stock recommendation by brokers for April 15, 2025
Stay updated with the latest news on Times of India. Get all the trending City News, India News, Business News, and Sports News. For Entertainment News, TV News, and Lifestyle Tips, visit Etimes.
Incyte Corp. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)
Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes ...